logo-loader

Amphion Innovations president on significant partner developments and strategy

Published: 11:11 14 Dec 2018 EST

Bob Bertoldi, president of Amphion Innovations PLC (LON:AMP) caught up with Proactive London’s Andrew Scott to discuss some of the big 2018 developments at the partner companies including Polarean Imaging (LON:POLX) and Motif Bio PLC (LON:MTFB)

Polarean’s recently raised US$4mln through a share placing - Amphion took part in the placing and will remain the largest shareholder, holding some 18.4mln shares, equivalent to 18.2% of the enlarged share capital.

Where Motif’s concerned, a new drug application (NDA) for its drug iclaprim has been filed with the US Food and Drug Administration earlier this year, and a decision is due by February 13 2019.

Amphion Innovations hails favourable court ruling

Richard Morgan, chief executive of Amphion Innovations (LON:AMP), explains the ins and outs of the ruling it has received in a US federal court relating to its patented intellectual property. He tells Proactive Investors that the company has been striving to protect a software patent related...

on 04/14/2014